
    
      The study includes a maximum 4-week Screening Period, a maximum 4-week Titration Period for
      early-stage Parkinson's disease 24-week Maintenance Period, a maximum 6-day De-escalation
      Period and 30-day Safety Follow-Up Period. The maximum study durations for an individual
      subject with early-stage Parkinson's disease will be 36 weeks.
    
  